Eli Lilly (LLY), Pfizer (PFE), and Johnson & Johnson (JNJ) have secured spots on China’s drug catalog, with a total of 19 medicines making the list, Amber Tong of Bloomberg reports. The government did not disclose average discounts, but these additions open a new market channel for the companies.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
- Salesforce (CRM) Wins AstraZeneca Deal, Becomes the Unified Global Platform
- FDA shift in drug study requirements sends trial runners lower
- FDA to reduce number of trials required for drug approvals, STAT reports
- Eli Lilly price target raised to $1,200 from $1,100 at BMO Capital